Intensive versus subcutaneous insulin in patients with hyperacute stroke: results from the randomized INSULINFARCT trial.

Charlotte Rosso 1 Jean-Christophe Corvol 2 Christine Pires Sophie Crozier Yohan Attal 1 Sophie Jacqueminet Sandrine Deltour Gurkan Multlu Anne Leger Isabelle Meresse Christine Payan 3 Yves Samson 1
1 NEMESIS-CRICM - Equipe NEMESIS - Centre de Recherches de l'Institut du Cerveau et de la Moelle épinière
CRICM - Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière
2 Fédération des Maladies du Système Nerveux
3 Service de Pharmacologie Clinique
Abstract : BACKGROUND AND PURPOSE: Intensive insulin therapy (IIT) has not yet proven its efficacy on stroke prognosis or in the reduction of MRI infarct growth. The INSULINFARCT study aims at determining in patients with hyperacute stroke whether IIT, with a better control of poststroke hyperglycemia, would reduce subsequent MRI infarct growth than usual care with subcutaneous insulin. METHODS: One hundred eighty patients with MRI-proven ischemic stroke and with National Institutes of Health Stroke Scale from 5 to 25 at admission (<6 hours) were randomized to receive IIT or usual subcutaneous insulin for 24 hours. Admission hyperglycemia was not required for recruitment. Control MRI and 3-month follow-up (with functional outcome and serious adverse events) were planned. The primary objective was to detect a difference in the proportion of patients with mean capillary glucose test <7 mmol/L during 24 hours. The secondary objective was to investigate whether IIT would reduce infarct growth. The analysis was planned in intention-to-treat. Patients with >3 missing capillary glucose test were excluded (n=4). RESULTS: The proportion of patients with mean capillary glucose test <7 mmol/L in the first 24 hours was higher in the IIT group (95.4% [83 of 87] versus 67.4% [60 of 89]; P<0.0001). The infarct growth was lower in the subcutaneous insulin group (median, 10.8 cm(3); 95% CI, 6.5-22.4 versus 27.9 cm(3); 14.6-40.7; 60% of increase; P=0.04). The 3-month functional outcome (45.6% [41 of 90] versus 45.6% [41 of 90]), death (15.6% [14 of 90] versus 10% [9 of 90]), and serious adverse events (38.9% [35 of 90] versus 35.6% [32 of 90]) were similar in the subcutaneous insulin and IIT group. CONCLUSIONS: The IIT regimen improved glucose control in the first 24 hours of stroke but was associated with larger infarct growths. IIT cannot be recommended in hyperacute ischemic stroke. Clinical Trial Registration- URL: http://clinicaltrials.gov. Unique Identifier: NCT00472381.
Type de document :
Article dans une revue
Stroke, American Heart Association, 2012, 43 (9), pp.2343-2349. 〈10.1161/STROKEAHA.112.657122〉
Liste complète des métadonnées
https://hal.inria.fr/hal-00795711
Contributeur : Olivier Colliot <>
Soumis le : jeudi 28 février 2013 - 18:03:14
Dernière modification le : jeudi 13 décembre 2018 - 01:34:25

Lien texte intégral

openaccess

Identifiants

Collections

ICM | UPMC | SORBONNE-UNIVERSITE

Citation

Charlotte Rosso, Jean-Christophe Corvol, Christine Pires, Sophie Crozier, Yohan Attal, et al.. Intensive versus subcutaneous insulin in patients with hyperacute stroke: results from the randomized INSULINFARCT trial.. Stroke, American Heart Association, 2012, 43 (9), pp.2343-2349. 〈10.1161/STROKEAHA.112.657122〉. 〈hal-00795711〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

350

Contact


archive-ouverte@inria.fr